AEGiS-WSJ: Letters to the Editor: Vaccines Offer Hope In Battle Against HIV Wall Street JournalImportant note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.
Click here to return to Wall Street Journal main menu




DonateNow



Letters to the Editor: Vaccines Offer Hope In Battle Against HIV

The Wall Street Journal - 24 Jun 1992
John F. Krowka, San Francisco


Your May 26 article on HIV vaccines was unduly pessimistic. It is true that the polymorphism of HIV, particularly in its envelope proteins, is likely to preclude the development of a "perfect" vaccine that would be 100% effective in the prevention or treatment of HIV infections. A large body of scientific evidence, however, indicates that vaccines currently in development may be useful, even if they fall short of this idealized goal. It is important to remember that vaccines, like other drugs, do not have to be perfect. They need only to show enough beneficial effects to justify their costs.

Some immune responses inhibit HIV and may be beneficial to individuals who are at risk of exposure to this virus or are already infected. By using a cocktail of proteins or peptides from the most common HIV types, it may be possible to stimulate immune responses selectively that would be effective against many or most HIV isolates. The approach pursued by the Merck/MedImmune/Repligen alliance is particularly appealing. By incorporating selected pieces of HIV into the tuberculosis vaccine BCG, it may be possible to stimulate strong and long-lasting immune responses to HIV. A recombinant HIV-BCG vaccine might be particularly useful in Third World countries.

A vaccine that protected only 50% of individuals from infection, prolonged the lives of infected individuals, and/or minimized disease symptoms would not be perfect, but it still would be extremely valuable.


920624
WJ920601


Copyright © 1992 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .